BioCentury
ARTICLE | Product Development

Step by step in psoriasis

Why guselkumab's use may be limited despite beating Humira in psoriasis Phase III

October 10, 2016 7:00 AM UTC

Johnson & Johnson's Phase III data could convince dermatologists to reach for guselkumab before an IL-17 inhibitor, but a combination of physician caution and payer restrictions will probably require patients to fail older, less effective biologics first.

Guselkumab is a subcutaneously administered mAb targeting the p19 subunit of IL-23. In the Phase III VOYAGE 1 trial, it demonstrated placebo-adjusted PASI scores similar to those seen in trials of IL-17 inhibitors, but with less frequent dosing and no signs ofde novo inflammatory bowel disease (IBD)...